AG
SAGE

Advisor Group’s Sage Therapeutics SAGE Stock Holding History

Advisor Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$48K Sell
648
-238
-27% -$29.3K ﹤0.01% 3445
2019
Q3 		$124K Buy
886
+19
+2% +$3.18K ﹤0.01% 2726
2019
Q2 		$159K Buy
867
+13
+2% +$2.22K ﹤0.01% 2496
2019
Q1 		$137K Buy
854
+13
+2% +$1.88K ﹤0.01% 2589
2018
Q4 		$82K Buy
841
+44
+6% +$5.04K ﹤0.01% 2810
2018
Q3 		$112K Buy
797
+483
+154% +$74.6K ﹤0.01% 2681
2018
Q2 		$50K Buy
314
+100
+47% +$15.7K ﹤0.01% 3112
2018
Q1 		$34K Sell
214
-2
-0.9% -$340 ﹤0.01% 3351
2017
Q4 		$35K Buy
216
+77
+55% +$7.46K ﹤0.01% 3338
2017
Q3 		$9K Buy
139
+81
+140% +$6.36K ﹤0.01% 4050
2017
Q2 		$4K Sell
58
-19
-25% -$1.37K ﹤0.01% 4332
2017
Q1 		$5K Hold
77
– – ﹤0.01% 4120
2016
Q4 		$3K Buy
77
+28
+57% +$1.32K ﹤0.01% 4130
2016
Q3 		$2K Sell
49
-24
-33% -$977 ﹤0.01% 4184
2016
Q2 		$1K Buy
+73
New +$2.43K ﹤0.01% 4266

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Advisor Group's SAGE Position: Q4 2019 in Review

Advisor Group reduced its Sage Therapeutics (SAGE) stake by 27% in Q4 2019, selling an estimated $29.3K and leaving 648 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #3445.

Advisor Group first reported a position in SAGE in Q2 2016 and has held it in 15 quarters since. The position peaked at $159K in Q2 2019. 267 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Advisor Group held 648 shares of Sage Therapeutics worth $48K as of Q4 2019.
  • Advisor Group sold 238 Sage Therapeutics shares in Q4 2019, an estimated $29.3K.
  • Sage Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3445 holding.
  • Advisor Group first reported a position in Sage Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Sage Therapeutics position peaked at $159K in Q2 2019.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.